

Transparency Reporting at Kyowa Kirin Methodological Note for 2022 data

1. Introduction

Kyowa Kirin Pharma B.V. is committed to supporting healthcare and the development of patient care across The Netherlands. We are pleased to do this through providing funds to Healthcare Organizations (HCOs) or Healthcare Practitioners (HCPs) and through engaging them for services that contribute to the improvement of patient care. In accordance with the CGR code, Kyowa Kirin Pharma B.V. publishes details about transfers of value to these individuals and organizations annually.

Each Kyowa Kirin affiliate in Europe is accountable for capturing and validating data in their nation and we make one disclosure per market. This disclosure covers transfers of value between [1st January 2022 to 31st December 2022 to HCPs, HCOs and POs which are registered in The Netherlands.

2. Scope of disclosure

This disclosure includes the following transfers of value:

CGR Category	CGR sub-category	Example activities (not exhaustive)
Donations and grants	N/A	<ul style="list-style-type: none"> • Donations to HCOs • Educational grants
Contribution to cost of events	Sponsorship agreements	<ul style="list-style-type: none"> • Sponsorship of congresses organised by HCOs or third-parties on their behalf
	Registration fees	<ul style="list-style-type: none"> • Funding of HCPs to attend congresses
	Travel , accommodation and meals	<ul style="list-style-type: none"> • HCP's travel, accommodation and meal costs for attending congresses
Fees for service	Fees	Fees for: <ul style="list-style-type: none"> • Chairing or attending Advisory Boards

		<ul style="list-style-type: none"> • Speaking engagements • Medical writing
	Related expenses	Travel, accommodation and meal expenses relating to the activities above.
Sponsorship Project	N/A	Sponsoring innovative and/or quality-enhancing activities aimed at directly or indirectly improving patient care or advancing medical science and which are not (or not fully) funded in any other regular manner and sponsoring of expenses of a thesis

If activities relate to retrospective non-interventional studies then they are included in Fees for Service, rather than Research and Development.

This disclosure excludes the following transfers of value:

- Informational and educational materials and items of medical utility, in line with article 9 of the CGR HCP/HCO Disclosure Code
- Logistical costs related to KKI-organised meetings (e.g. room hire)

As relates to transfers of value to HCPs, HCOs and POs, this disclosure does not include:

- Donations to non-HCOs
- Research and Development transfer of Values. This is disclosed on our company website [Transparantie - Kyowa Kirin Ltd \(kyowa-kirin.com\)](https://www.kyowa-kirin.com) on an aggregated level.

Some HCPs continue to provide advice to the healthcare community after they have retired. Generally KKI include such HCPs in the applicable regulation's definition of an HCP, however this depends on their role and ability to prescribe and influence.

3. Date of Transfers of Value

The date of the transfers of value included in this disclosure is based on date of payment (where the transfer of value is a payment).



If the transfer of value is a benefit in kind, it is based on the date the recipient received the benefit.

4. Direct and Indirect Transfers of Value

For direct transfers of value, the recipient is considered to be the person or entity holding the bank account receiving the money.

Kyowa Kirin Pharma B.V. also provides indirect transfers of value.

In the case of payments that are made through Clinical Research organizations, these are included under Research and Development and reported on our corporate website.

Where a third party has been appointed by an HCO to manage an event, and where the HCO benefits from the transfer of value, these transfers of value are disclosed against the HCO.

Where the service is provided by an HCP, and where the HCO benefits from the transfer of value, these transfers of value are disclosed against the HCP.

Where third parties are appointed by KKI to make travel and accommodation arrangements for HCPs, the transfers of value are reported against the HCP who received the benefit.

5. Cross-border activities

KKI makes best efforts to capture and report all transfers of value to HCPs and HCOs with primary practice in a country with EFPIA Disclosure Code or other transparency reporting requirements. The country of disclosure is based on the HCP's principal practice or the HCO's country of registration

6. Consent

In The Netherlands HCOs, HCPs and POs are reported without the need for consent.

7. Disclosure

Our report of transfers of value in 2022 is published on [Stichting Transparantieregister Zorg - Home](#) in Dutch.



The currency used for disclosure is Euros.

In the case that payments are made in a currency other than Euros the payment amount is converted to Euros using the daily exchange rate between the two currencies on the day of payment.

All Transfers of Value excluding VAT:

- Fee for Service - honorarium
- Contribution to costs of events – sponsorship of congresses

All Transfers of Value including VAT

- Fee for Service - expenses
- Sponsoring project
- Contribution to costs of events - hospitality

Any questions regarding this disclosure should be directed to karin.vanhagen@kyowakirin.com.